Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MY-KIDNEY
2024-510723-18-00Phase 2Authorised
- Sponsor
- Central Denmark Region
- Start
- Sep 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic adipose-derived mesenchymal stromal cells in Chronic humoral rejection (cABMR), sponsored by Central Denmark Region. Primary endpoints: Feasibility of MSC infusion, Safety: infusional toxicity and 1 more. Planned start Sep 2026; status: authorised.
02
Drugs
allogeneic adipose-derived mesenchymal stromal cells
03
Conditions
Chronic humoral rejection (cABMR)
Beyond the preview
Go deeper on 2024-510723-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510723-18-00.